<DOC>
	<DOCNO>NCT00278122</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Biological therapy , GM-CSF , may stimulate immune system different way stop tumor cell grow . Giving paclitaxel together GM-CSF may effective treat melanoma . PURPOSE : This phase II trial study well give paclitaxel together GM-CSF work treat patient stage III stage IV melanoma remove surgery .</brief_summary>
	<brief_title>Paclitaxel GM-CSF Treating Patients With Stage III Stage IV Melanoma That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess activity paclitaxel sargramostim ( GM-CSF ) , term objective clinical response rate ( complete response [ CR ] partial response [ PR ] ) , patient advance unresectable melanoma . Secondary - Evaluate duration response , time progression , overall survival patient treat regimen . - Determine serum cytokine level ( GM-CSF , IFN-γ , aldesleukin , recombinant interleukin-4 , IL-10 ) patient . OUTLINE : This open-label study . Patients receive paclitaxel IV 3 hour day 1 sargramostim ( GM-CSF ) subcutaneously day 4-17 . Treatment repeat every 21 day 12 course absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 2 additional course therapy beyond CR 12 course . After study treatment , patient follow every 3-6 month least 3 year . PROJECTED ACCRUAL : A total 42 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm unresectable stage III IV melanoma cutaneous , mucosal , unknown primary site Unresectable stage III disease , define meet 1 follow criterion : Regional metastasis , judgement treat physician , surgically resect clear margin Regional metastasis surgically resect clear margin extensive surgery inadvisable unacceptable treat physician and/or patient Staging cutaneous mucosal melanoma base revised American Joint Committee Cancer ( AJCC ) stag system Must measurable disease define Response Evaluation Criteria Small Tumors ( RECIST ) criteria No ocular melanoma Patients brain metastasis may eligible follow true : Total number brain metastasis ever ≤ 3 Each brain metastasis completely remove surgery unresected brain metastasis treat stereotactic radiosurgery Stereotactic radiosurgery , gamma knife , use 1 week study entry No evident growth brain metastasis since treatment No brain metastasis &gt; 2 cm diameter study entry PATIENT CHARACTERISTICS : ECOG performance status 01 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 9 g/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Bilirubin normal Creatinine ≤ 1.5 time ULN No New York Heart Association class III IV heart disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No previous concurrent autoimmune disorder require cytotoxic immunosuppressive therapy No autoimmune disorder visceral involvement The following condition allow : Laboratory evidence autoimmune disease ( e.g. , positive ANA titer ) without symptom Clinical evidence vitiligo Other form depigmenting illness Mild arthritis require steroidal antiinflammatory drug HIV negative Hepatitis C negative No serious poorly control medical condition could exacerbate complicate compliance study therapy PRIOR CONCURRENT THERAPY : No 1 previous chemotherapy regimen metastatic melanoma No previous paclitaxel No chemotherapy , interferon , growth factor , interleukin , radiotherapy ( exclude gamma knife therapy brain metastasis ) within past 4 week No surgical resection metastatic lesion within past 4 week No investigational medication within past 4 week study No nitrosoureas ( e.g. , carmustine lomustine ) within past 6 week study treatment No concurrent chemotherapy , interferon , growth factor , interleukin , illegal drug , radiotherapy , surgery , steroid therapy No concurrent oral injectable hydrocortisone ( dose &gt; 15 mg per day ) equivalent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>